Research Updates

Back to project

Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome): update of August 28, 2026

What's new and why it matters

  1. The FDA has added a boxed warning for ferric carboxymaltose due to risks of low phosphate levels. This action came after a petition led by Dr. Scott Olitsky from Cure HHT. Based on: 1

Materials in this update

  1. FDA Adds Boxed Warning to Ferric Carboxymaltose Following Petition Led by Cure HHT’s Dr. Scott Olitsky
    News

    Aug 24, 2026

    The FDA added a warning to ferric carboxymaltose, highlighting risks of low phosphate levels after a petition by Dr. Scott Olitsky from Cure HHT.

All updates for Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome)

Email language